WO2012134194A2 - Herbal compositions for treating neurological diseases and improving memory impairment - Google Patents
Herbal compositions for treating neurological diseases and improving memory impairment Download PDFInfo
- Publication number
- WO2012134194A2 WO2012134194A2 PCT/KR2012/002330 KR2012002330W WO2012134194A2 WO 2012134194 A2 WO2012134194 A2 WO 2012134194A2 KR 2012002330 W KR2012002330 W KR 2012002330W WO 2012134194 A2 WO2012134194 A2 WO 2012134194A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- extract
- red sage
- present disclosure
- improving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present disclosure relates to a herbal composition for preventing or treating neurological diseases or improving brain or cognitive function. More particularly, it relates to a herbal composition for protecting nerve cells and improving neurological diseases, which includes an extract of Euphoria longan fruit, red sage and Gastrodia elata.
- Dementia refers to severe loss of global cognitive ability without disorder of consciousness, leading to loss of mental (intellectual) ability and ability for social activities. Dementia may be caused by various causes and is accompanied by memory impairment, speech impediment, disturbance in visuospatial ability, apraxia, agnosia, impairment of computational ability, frontotemporal lobar degeneration, disturbance in executive function, or the like.
- Dementia can be classified into Alzheimer's dementia, vascular dementia and other dementia according to occurrence.
- Alzheimer's disease is the leading cause of dementia, accounting for about 50-60%.
- the impairment of cognitive function and damage of nerve cells in patients with dementia are related with disorder in transport, generation, secretion and removal of neurotransmitters.
- Representative neurotransmitters are acetylcholine and glutamate. It is reported that patients with dementia show decrease and reduced function of the neurotransmitter acetylcholine in brain tissues, which is important in learning and memory. Glutamate is an important excitatory neurotransmitter playing a key role in learning and memory in the central nervous system.
- NMDA N-methyl-D-aspartate
- tacrine has the adverse effect of hepatotoxicity (Leonard, World Psychiatry 3 ⁇ 84-88 (2004))
- donepezil has adverse effects including nausea, vomiting and diarrhea (Burns et al., Dement Geriatr Cogn Disord 10: 237-244 (1999))
- rivastigmine has central and peripheral cholinergic adverse effects at high concentrations (Leonard, World Psychiatry 3: 84-88, 2004)
- galantamine has adverse effect in the gastrointestinal tract (Tariot et al., Neurology 54: 2269-2276, 2000).
- the inventors of the present disclosure have explored natural materials capable of preventing or treating neurological diseases, especially dementia or memory impairment, that can be quickly absorbed into the human body without adverse effects. As a result, they have found out that a composition including an extract of Euphoria longan fruit, red sage and Gastrodia elata improves memory impairment and effectively protects nerve cells from substances causing neurological diseases, particularly dementia.
- the present disclosure is directed to providing a pharmaceutical composition for preventing or treating neurological diseases.
- the present disclosure is also directed to providing a food composition for improving neurological diseases.
- the present disclosure is also directed to providing a method for preventing or treating neurological diseases.
- the present disclosure is also directed to providing a food composition for improving brain or cognitive function.
- the present disclosure is also directed to providing a method for improving brain or cognitive function.
- Fig. 1 shows the effect of treatment of the brain of a male mouse with donepezil, Gastrodia elata extract or HX107M on the activity of acetylcholinesterase (AChE).
- Fig. 2 shows the effect of treatment of the brain of a male mouse with donepezil, HX107M, HX107N including ophiopogon root on the activity of AChE.
- Fig. 3 shows the effect of oral administration of donepezil, HX107N or red sage extract on the activity of AChE in the brain of a male mouse.
- Fig. 4 shows the effect of HX107N on improvement in learning ability and memory in the probe test after administration of amyloid ⁇ into the cerebral ventricle.
- Symbols # and ## respectively denote significance at p ⁇ 0.05 and p ⁇ 0.01 and * denotes comparison with the non-treated group at p ⁇ 0.05.
- Fig. 5 shows the effect of HX107N on improvement in learning ability and memory in the passive avoidance test after administration of amyloid ⁇ into the cerebral ventricle.
- Symbols # and ## respectively denote significance at p ⁇ 0.05 and p ⁇ 0.01 and * denotes comparison with the non-treated group at p ⁇ 0.05.
- Fig. 6 shows the effect of HX107N on inhibition of brain damage in histological examination after administration of amyloid ⁇ into the cerebral ventricle.
- the present disclosure provides a pharmaceutical composition for preventing or treating neurological diseases comprising: (a) an extract of a mixture of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient; and (b) a pharmaceutically acceptable carrier.
- the present disclosure provides a food composition for improving neurological diseases comprising an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient.
- the present disclosure provides a method for preventing or treating neurological diseases.
- the inventors of the present disclosure have explored natural materials capable of preventing or treating neurological diseases, especially dementia or memory impairment, that can be quickly absorbed into the body without adverse effects. As a result, they have found out that a composition including an extract of Euphoria longan fruit, red sage and Gastrodia elata improves memory impairment and effectively protects nerve cells from substances causing neurological diseases, particularly dementia.
- the present composition comprises an extract of a mixture of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient.
- an extract of a mixture of Euphoria longan fruit, red sage and Gastrodia elata encompasses not only an extract obtained from a mixture of Euphoria longan fruit, red sage and Gastrodia elata but also a mixture of extracts obtained from Euphoria longan fruit, red sage and Gastrodia elata, respectively.
- an extract of a mixture of Euphoria longan fruit, red sage and Gastrodia elata refers to an extract obtained from a mixture of Euphoria longan fruit, red sage and Gastrodia elata.
- Euphoria longan fruit is obtained by drying the aril of Euphoria longan Steud., an evergreen tree in the family Sapindaceae. It has long been known to be effective in strengthening the heart and pancreas, replenishing qi and blood, and tranquilizing the mind. According to the book on medicinal plants, Shennong Bencaojing, Euphoria longan fruit controls the sinister qi of the five viscera, tranquilizes the mind, sharpens appetite and promotes digestion (Chang-Min Kim et al., Grand Dictionary of Chinese Medicine, 3194-3196, 2004).
- Red sage ⁇ Salvia miltiorrhiza BGE is a perennial plant in the family Lamiaceae.
- the dried root and rhizome of red sage are known to be effective in treating chest and hypochondriac pain, numb pain caused by wind and dampness, abdominal pain and swelling, and menstrual pain by promoting blood flow and removing stasis (Hocheol Kim, Herbal Pharmacology, 332-333, 2004).
- Gastrodia elata is a saprophytic perennial herb in the family Orchidaceae.
- the dried tuber of Gastrodia elata BL has been used to treat various convulsive diseases and nervous system disorders such as headache, dizziness, numbness, etc. by regulating the liver qi (Chang-Min Kim et al., Grand Dictionary of Chinese Medicine, 4105-4110, 2004; Byung-Soo Kang et al., Herbology, 504-505, 2000).
- the term “Euphoria longan fruit extract” refers to an extract obtained from the aril of Euphoria longan Steud.
- the term “red sage extract” refers to an extract obtained from various parts (e.g., root, rhizome, fruit, stem, leaf and flower) of red sage. Specifically, the red sage extract may be an extract obtained from the root or rhizome of red sage.
- the term “Gastrodia elata extract” refers to an extract obtained from various parts (e.g., root, tuber, fruit, stem, leaf and flower) of Gastrodia elata. Specifically, the Gastrodia elata extract refers to an extract obtained from the tuber of Gastrodia elata.
- the extract used in the present disclosure may be obtained using extraction solvents known in the art, specifically, (a) water, (b) Ci-C 4 anhydrous or aqueous low alcohol (e.g., methanol, ethanol, propanol, butanol, n-propanol, isopropanol, n-butanol, etc.), (c) a mixture of the low alcohol with water, (d) acetone, (e) ethyl acetate, (f) chloroform, (g) 1,3-butylene glycol, (h) hexane, (i) diethyl ether or (j) butyl acetate.
- extraction solvents known in the art, specifically, (a) water, (b) Ci-C 4 anhydrous or aqueous low alcohol (e.g., methanol, ethanol, propanol, butanol, n-propanol, isopropanol, n-butanol, etc.
- the extracts of Euphoria longan fruit, red sage and Gastrodia elata of the present disclosure also include ones obtained after purification of the extracts obtained using the above-described solvents.
- the extracts obtained after various purification processes such as filtration through ultrafiltration membrane having a predetermined molecular weight cut-off value, separation by various chromatographic techniques (based on size, charge, hydrophobicity or affinity), etc. are included in the extracts of Euphoria longan fruit, red sage and Gastrodia elata of the present disclosure.
- the extracts of Euphoria longan fruit, red sage and Gastrodia elata of the present disclosure may be prepared into powder form through further processes such as distillation under reduced pressure followed by freeze drying or spray drying.
- the mixture used in the composition of the present disclosure further comprises a plant for improving blood circulation.
- the plant for improving blood circulation includes any one known to be effective in invigorating or improving blood circulation for enabling fast and effective absorption of the composition of the present disclosure into the body.
- the mixture used in the composition of the present disclosure may further comprise a plant for improving blood circulation which is selected from a group consisting of ophiopogon root, turmeric, Cnidium officinale, Angelica gigas, peach kernel, safflower, Achyranthes japonica, Caesalpinia sappan, frankincense, motherwort, Curcuma longa, bur-reed rhizome, honey locust thorn and myrrh (Byung-Soo Kang et al., Herbology, 408-441, 2000). More specifically, the plant for improving blood circulation used in the present disclosure may be ophiopogon root or turmeric.
- Ophiopogon root is the dried tuberous root of Liriope platyphylla Wang et Tang or Ophiopogon japonicas Ker Gawl, which are perennial in the family Liliaceae.
- Ophiopogon root is moist in nature and is known to treat dry cough, hematemesis, heartburn, hydrodipsomania, or the like by generating body fluid, moistening dryness and cooling down the excessive heart qi (Chang-Min Kim et al., Grand Dictionary of Chinese Medicine, 1262-1269, 2004; Byung-Soo Kang et al., Herbology, 588-589, 2000).
- the ophiopogon root further included in the composition of the present disclosure may be the root of Ophiopogon japonicas.
- Turmeric is the tuberous root of Curcuma longa Linne, Curcuma aromatica Salisbury or Curcuma zedoaria (Berg.) Rose, of the family Zingiberaceae, and contains curcumin, turmerone, zingiberene, etc.
- turmeric has been known to promote the secretion of gastric juice, promote urination, have a detoxifying effect, promote regeneration of liver cells and have anti-inflammatory and antioxidant effects (Chang-Min Kim et al., Grand Dictionary of Chinese Medicine, 3282-3286, 1997).
- turmeric is known to help blood circulation and remove stasis (Byung-Soo Kang et al., Herbology, 408-441, 2000).
- the plant for improving blood circulation helps blood circulation and exhibits detoxifying effect when administered into the body.
- the plant for improving blood circulation used in the present disclosure helps blood circulation by promoting blood flow, improving contraction of heart muscles or removing stasis and has a detoxifying effect of controlling or removing toxic substances absorbed or accumulated in the body.
- the content of the ophiopogon root or turmeric of the extract in the composition of the present disclosure is not particularly limited as long as the desired effect of blood circulation improvement or detoxification is achieved. Those skilled in the art will be able to determine the content of the further included plant to suit the purpose of the present disclosure.
- the ophiopogon root or turmeric of the extract may be included in an amount of 1-99 wt%, more specifically 10-80 wt%, most specifically 30-70 wt%, based on the total weight of the mixture, but is not limited thereto.
- the pharmaceutical composition of the present disclosure comprises a pharmaceutically effective amount of an extract of Euphoria longan fruit, red sage and Gastrodia ata.
- pharmaceutically effective amount refers to an amount sufficient to achieve the effect or activity of the extract of Euphoria longan fruit, red sage and Gastrodia elata and is not particularly limited as long as the purpose of the present disclosure can be achieved.
- the Euphoria longan fruit may be included in an amount of 1-99 wt%, more specifically 10-80 wt%, most specifically 20-60 wt%, based on the total weight of the mixture
- the Gastrodia elata may be included in an amount of 0.1-99 wt%, more specifically 1-80 wt%, most specifically 5-60 wt%, based on the total weight of the mixture
- the red sage may be included in an amount of 0.1-99 wt%, more specifically 0.5-80 wt%, most specifically 1-50 wt%, based on the total weight of the mixture, although not being limited thereto.
- the pharmaceutical composition of the present disclosure comprises a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier included in the pharmaceutical composition of the present disclosure may be one commonly used in the art. Examples include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but are not limited thereto.
- the pharmaceutical composition of the present disclosure may further include, in addition to the above-described components, a lubricant, a wetting agent, a sweetener, a fragrance, an emulsifier, a suspending agent, a preservative, or the like.
- a lubricant for example, a lubricant, a wetting agent, a sweetener, a fragrance, an emulsifier, a suspending agent, a preservative, or the like.
- composition of the present disclosure may be administered orally or parenterally, specifically orally.
- An appropriate dosage of the pharmaceutical composition of the present disclosure may be determined variously depending on such factors as preparation method, administration method, age, body weight and sex of the patient, pathological condition, diet, administration time, administration route, excretion rate or response sensitivity.
- a general dosage of the pharmaceutical composition of the present disclosure for an adult is 0.001-1000 mg/kg.
- the pharmaceutical composition of the present disclosure may be prepared into a unit dosage form or multiple dosage form along with a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily employed by those skilled in the art.
- the formulation may be in the form of solution in oily or aqueous medium, suspension, syrup, emulsion, extract, dust, powder, granule, tablet or capsule, and may further include a dispersant or stabilizer.
- the composition of the present disclosure may also be provided as a food composition.
- the composition of the present disclosure may comprise, in addition to the extract of the mixture of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient, ingredients commonly added for preparation of food.
- ingredients commonly added for preparation of food For example, proteins, carbohydrates, fats, nutrients, seasoning or flavors may be added.
- the carbohydrate may be, for example, a sugar such as a monosaccharide, e.g. glucose, fructose, etc., a disaccharide, e.g. maltose, sucrose, oligosaccharide, etc. or a polysaccharide, e.g. dextrin, cyclodextrin, etc.
- the flavor may be a natural flavor [thaumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.)] or a synthetic flavor (saccharin, aspartame, etc.).
- the food composition of the present disclosure when prepared as a drink, it may further comprise, in addition to the extract of the mixture of Euphoria longan fruit, red sage and Gastrodia elata, citric acid, high-fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, eucommia extract, jujube extract, licorice extract, or the like.
- composition of the present disclosure may be used to prevent or treat various neurological diseases. Specifically, the composition of the present disclosure may be used to prevent or treat degenerative nerve disease or mental disorder.
- the degenerative nerve disease may be dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease or amyotrophic lateral sclerosis.
- the term “dementia” refers to a disease, disorder or condition characterized by severe loss of cognitive ability. Dementia can be classified into Alzheimer's dementia, vascular dementia and other dementia.
- the composition of the present disclosure is effective in treating Alzheimer's disease. Excess amyloid ⁇ peptide buildup is associated with Alzheimer's disease. Decreasing amyloid ⁇ in the neuritic space slows the progress of Alzheimer's disease. Although the formation process of amyloid ⁇ has not been completely elucidated scientifically, the composition of the present disclosure can prevent or treat Alzheimer's disease by inhibiting the detrimental nervous insult of amyloid ⁇ as demonstrated in the following examples.
- Vascular dementia is the second most common form of dementia. This disease is caused by the narrowing or blockage of blood vessels supplying blood to the brain. Also, repeated strokes may lead to vascular dementia.
- the composition of the present disclosure may be useful in the treatment of vascular dementia.
- the mental disorder may be depression, schizophrenia or posttraumatic stress disorder.
- Depression is a mental disorder that can be caused by stress. It often leads to an extreme result such as suicide and is recognized as a very important disease owing to high relapse and fast increase.
- Disorders of brain neurotransmitters such as adrenaline, dopamine or serotonin are known as the cause of depression. Depression is also accompanied by brain damage such as hippocampal atrophy, suppressed neurogenesis in adults, or the like.
- tricyclic antidepressants TCAs
- amitriptyline which is widely prescribed inside and outside Korea, has various adverse effects.
- the selective serotonin reuptake inhibitor (SSRI) fluoxetine was developed in the USA. With reduced adverse effects, greatly improved compliance and reduced treatment failure, it ranked 7th among the world's 20 best-selling drugs in 1996.
- the SSRIs do not show big difference from TCAs in terms of effect and have severe drug interaction problems.
- the extract of Euphoria longan fruit, red sage and Gastrodia elata of the present disclosure prevent the degeneration of pyramidal cells in the dentate gyrus of the hippocampus from nervous insult, for example, caused by amyloid ⁇ , as demonstrated in the following examples. This suggests the potential of the composition of the present disclosure as antidepressant.
- the present disclosure provides a food composition for improving brain or cognitive function comprising an extract of Euphoria longan fruit, red sage and Gastrodia elata extracts as an active ingredient.
- the present disclosure provides a method for improving brain or cognitive function, comprising: administering to a subject a composition comprising an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient.
- the mixture used in the composition of the present disclosure further comprises a plant for improving brain or cognitive function selected from learning ability, memory and concentration. More specifically, the mixture used in the composition of the present disclosure may further comprise a plant for improving memory impairment.
- AChE inhibitors tacrine, donepezil, rivastigmine and galantamine have been developed as treatment for Alzheimer's disease, it is difficult to directly regenerate the brain cells or inhibit damage to the brain cells.
- composition of the present disclosure comprising the extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient reduces the activity of AChE and suppresses nerve damage caused by nervous insult with few adverse effects to the human body, it may be very usefully used for improvement of memory impairment.
- the present disclosure provides a composition for preventing or treating neurological diseases comprising an extract of Euphoria longan fruit, red sage and Gastrodia ata. Since it protects nerve cells from nervous insult caused by, for example, amyloid ⁇ , it is very effective in preventing or treating neurological diseases, especially dementia.
- composition of the present disclosure has a very superior effect of improving memory.
- composition of the present disclosure can be quickly absorbed into the human body with few adverse effects.
- Test Example 1 AChE activity inhibition effect according to mixing proportion of extracts
- AChE activity assay was performed according to Ellman's method (Ellman et al., Biochem Pharmacol 7: 88-95 (1961)) using the extracts from the mixtures prepared in Preparation Example 1.
- the brain of a 5-week-old male ICR mouse (Orient Bio, Korea) was extracted after acclimatization for a week.
- the brain was homogenized to 10 volume equivalents of the brain using 12.5 mM sodium phosphate buffer (pH 7.0).
- the homogenate was centrifuged at 3000 rpm for 10 minutes at 4°C and the supernatant was obtained.
- Table 3 shows AChE activity inhibition effect (%) according to mixing proportions of the extracts.
- Test Example 2 Comparison of AChE activity inhibition effect of HX107M and Gastrodia elata extract
- AChE activity assay was performed according to Ellman's method (Ellman et al., Biochem Pharmacol 1 88-95, (1961)) using HX107M and Gastrodia elata extract.
- the brain of a 5-week-old male ICR mouse (Orient Bio, Korea) was extracted after acclimatization for a week.
- the brain was homogenized to 10 volume equivalents of the brain using 12.5 mM sodium phosphate buffer (pH 7.0).
- the homogenate was centrifuged at 3000 rpm for 10 minutes at 4°C and the supernatant was obtained.
- buffer, 75 mM acetylthiocholine iodide and 10 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DNTB) were added to a 96-well microplate and the plate was treated with HX107M and Gastrodia elata extract at 5.83 mg/mL and 0.83 mg/mL. Then, after adding the supernatant obtained from the mouse to the plate, reaction was incubated at room temperature for 10 minutes in the dark. After the reaction was completed, the change in absorbance at 405 nm was measured for 40 minutes with 2-minute intervals. As a result, HX107M showed an AChE activity inhibition effect of 40.35%, whereas the Gastrodia ata extract showed no AChE activity inhibition effect (Fig. 1).
- Test Example 3 Comparison of AChE activity inhibition effect of HX107M and HX107N
- Ophiopogon japonicas ox turmeric which is well known to improve blood circulation, was mixed with HX107M and the effect on inhibition of AChE activity of HX107M was investigated. Of the two candidates, Ophiopogon japonicas was finally selected since it further has the detoxifying effect and is capable of improving the safety of composition of the present disclosure.
- the mixture extract No. 5 prepared in Preparation Example 3 was named as HX107N.
- HX107N at 2.92 mg/mL and 5 mg/mL, respectively.
- HX107M and HX107N showed comparable AChE inhibition activity of 29.02% and 29.83% (Fig. 2). This suggests that the addition of ophiopogon root does not significantly affect the AChE inhibition activity.
- HX107N which further comprises Ophiopogon japonicas having blood circulation improving and detoxifying effects.
- Test Example 4 Comparison of AChE activity inhibition effect of HX107N and red sage extract
- the AChE inhibition activity of HX107N and red sage extract was compared as follows. 5-week-old male ICR mice (Orient Bio, Korea) were purchased and acclimatized for a week. For in vivo AChE activity assay, control substance (donepezil 1 mg/kg), HX107N (200 mg/kg) or red sage extract (50 mg/kg) was orally administered once to the mice (3 per each group). 6 hours later, the hippocampus was isolated and homogenized using 1 M phosphate buffer (pH 8.0). The in vivo AChE activity of the obtained homogenate was measured using the Amplex red assay kit (Molecular Probe, USA).
- HX107N showed an AChE activity inhibition effect of about 64.4%, whereas the red sage extract showed no AChE activity inhibition effect (Fig. 3).
- Test Example 5 Water maze test for testing spatial memory improving effect of HX107N in rat model with dementia induced by amyloid ⁇
- 60 male Sprague-Dawley rats (Samtako Bio Korea, Korea) were purchased and acclimatized for 7 days. All test animals were allowed free access to food and water in a cage maintained at constant temperature and humidity, under a 12-hour light/dark cycle.
- the 60 rats were grouped into 6 groups (10 per each group) and were orally administered with HX107N (10, 100 and 200 mg/kg), red ginseng (150 mg/kg, Korea Ginseng Corp., Korea) or saline, as control, for 4 weeks. Then, 2.2 nM amyloid ⁇ 1-42 peptide (Sigma, USA) was injected into the cerebral ventricle of the rats using a stereotaxic apparatus to induce dementia.
- Table 4 shows the spatial memory improving effect of HX107N in the water maze test.
- the symbols denote the following significance.
- Test Example 6 Passive avoidance test for testing memory improving effect of HX107N in rat model with dementia induced by amyloid ⁇
- 60 male Sprague-Dawley rats (Samtako Bio Korea, Korea) were purchased and acclimatized for 7 days. All test animals were allowed free access to food and water in a cage maintained at constant temperature and humidity, under a 12-hour light/dark cycle.
- the 60 rats were grouped into 6 groups (10 per each group) and were orally administered with HX107N (10, 100 and 200 mg/kg), red ginseng (150 mg/kg, Korea Ginseng Corp., Korea) or saline, as control, for 4 weeks. Then, 2.2 nM amyloid ⁇ -42 peptide was injected into the cerebral ventricle of the rats using a stereotaxic apparatus to induce dementia. One week later, passive avoidance test was carried out to test memory.
- amyloid ⁇ resulted in the decline of memory, with 205.12 ⁇ 34.69 seconds of latency time for the non-treated group and 93.48 ⁇ 32.82 seconds of latency time for the amyloid ⁇ -administered group, within the time limit of 300 seconds.
- the group treated with HX107N showed significant improvement in memory, with 190.90 ⁇ 30.26 seconds of latency time for 100 mg/kg and 201.05 ⁇ 25.84 seconds of latency time for 200 mg/kg (Fig. 5).
- Test Example 7 Histological examination of hippocampus in rat model with dementia induced by amyloid ⁇ After the behavioral tests were completed, the rats were anesthetized with diethyl ether and perfused with saline through the heart. Then, the brain was taken out and fixed in 10% neutral-buffered formalin. The degree of degeneration of the nerve cells in the hippocampus was observed by hematoxylin & eosin staining. As a result, the group treated with amyloid ⁇ showed degeneration of pyramidal cells, which are involved in memory, in the dentate gyrus of the hippocampus, as compared to the non-treated group. The group treated with 200 mg/kg HX107N showed less damage (Fig. 6).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137026397A KR101601860B1 (en) | 2011-03-29 | 2012-03-29 | Herbal Compositions for Treating Neurological Diseases and Improving Memory Impairment |
JP2014502473A JP5832628B2 (en) | 2011-03-29 | 2012-03-29 | Herbal medicine composition for treatment of neurological disorders and improvement of memory loss |
CN201280016132.2A CN103533948A (en) | 2011-03-29 | 2012-03-29 | Herbal compositions for treating neurological diseases and improving memory impairment |
US14/007,095 US10058583B2 (en) | 2011-03-29 | 2012-03-29 | Herbal compositions for treating neurological diseases and improving memory impairment |
EP12762802.2A EP2691102B1 (en) | 2011-03-29 | 2012-03-29 | Herbal compositions for treating neurological diseases and improving memory impairment |
ES12762802T ES2715290T3 (en) | 2011-03-29 | 2012-03-29 | Herbal compositions for the treatment of neurological diseases and improvement of memory impairment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110028086 | 2011-03-29 | ||
KR10-2011-0028086 | 2011-03-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012134194A2 true WO2012134194A2 (en) | 2012-10-04 |
WO2012134194A3 WO2012134194A3 (en) | 2013-03-21 |
Family
ID=46932142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/002330 WO2012134194A2 (en) | 2011-03-29 | 2012-03-29 | Herbal compositions for treating neurological diseases and improving memory impairment |
Country Status (7)
Country | Link |
---|---|
US (1) | US10058583B2 (en) |
EP (1) | EP2691102B1 (en) |
JP (1) | JP5832628B2 (en) |
KR (1) | KR101601860B1 (en) |
CN (2) | CN103533948A (en) |
ES (1) | ES2715290T3 (en) |
WO (1) | WO2012134194A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083490A (en) * | 2013-02-18 | 2013-05-08 | 柳少逸 | Traditional Chinese medicine for treating post-traumatic brain syndrome |
CN103272010A (en) * | 2013-06-11 | 2013-09-04 | 陈静静 | Traditional Chinese medicine formula for orthopedic nursing |
CN104920001A (en) * | 2014-03-20 | 2015-09-23 | 四川代代为本农业科技有限公司 | Stereo-planting method for interplanting climbing vegetables with ophiopogon japonicas |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101540107B1 (en) * | 2015-02-05 | 2015-07-30 | 주식회사 다림바이오텍 | Manufacturing method of oral formulations using repeated successive dilution and shaking |
KR101704918B1 (en) * | 2015-08-24 | 2017-02-09 | 동국대학교 경주캠퍼스 산학협력단 | Pharmaceutical composition comprising the extracts of mixed crude drugs for the prevention or treatment of the Parkinson's disease |
KR101725979B1 (en) | 2016-04-12 | 2017-04-12 | 유한회사한풍제약 | A composition of myrrh extracts for treating memory impairment |
CN105998316B (en) * | 2016-05-23 | 2019-12-03 | 齐齐哈尔医学院 | A kind of Chinese medicine composition for treating senile dementia and its specific preparation method and related application |
CN107970420A (en) * | 2017-12-24 | 2018-05-01 | 南宁多灵生物科技有限公司 | A kind of medicine for treating shaking plasy |
KR102014824B1 (en) * | 2018-05-09 | 2019-08-28 | 주식회사 진생바이팜 | Health food composition for vascular relaxation and anti-thrombotic effects comprising Black Ginseng Radix, Salviae Miltiorrhizae Radix, Leonuri Herba and Cnidii Rhizoma |
US11975039B2 (en) | 2018-05-10 | 2024-05-07 | Helixmith Co., Ltd. | Herbal composition for treatment of attention deficit hyperactivity disorder |
CN108902937B (en) * | 2018-06-11 | 2021-08-27 | 湖州维义生物科技股份有限公司 | Functional food for preventing senile dementia and preparation method thereof |
EP4043024A4 (en) * | 2019-10-10 | 2023-10-18 | Mthera Pharma Co., Ltd. | Composition for preventing or treating neurodegenerative diseases containing mixed herbal extract of genkwae flos, clematidis radix, and gastrodiae rhizoma |
CN112156169A (en) * | 2020-11-16 | 2021-01-01 | 李红梅 | Traditional Chinese medicine composition for treating schizophrenia |
CN113230370A (en) * | 2021-06-11 | 2021-08-10 | 曹晓芸 | Traditional Chinese medicine formula for treating cognitive dysfunction after cerebral infarction |
CN116270901B (en) * | 2022-12-26 | 2023-11-10 | 广西中医药大学 | Chinese herbal compound and pharmaceutical composition thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181966A (en) | 1997-09-19 | 1998-05-20 | 薛廷民 | Medicine for senile dementia and its preparation |
KR20030071035A (en) | 2002-02-27 | 2003-09-03 | 씨.에프. 주식회사 | Gastrodia elata Blume extracts having neuroprotection activity and preventive and therapeutic composition for dementia containing the same |
CN1242780C (en) | 2002-05-31 | 2006-02-22 | 丁勤章 | Medicine compsn. for antagonizing poison-side effect caused by psychotropic drug |
KR20040015828A (en) | 2002-08-07 | 2004-02-21 | 박기원 | Herb Extract which Has Psychologically Relieving Effect |
CN1552838A (en) | 2003-08-18 | 2004-12-08 | 许盛英 | Xinxuekang health-care spirit and its production |
US20050142223A1 (en) * | 2003-12-29 | 2005-06-30 | Jiao Gong | Pharmacological activity and manufacturing method of the production produced by 16 kinds of plant compound to improve memory |
US20060148727A1 (en) | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
KR100725839B1 (en) | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction |
KR20070040209A (en) | 2005-10-11 | 2007-04-16 | 일성신약주식회사 | Composition comprising the fraction of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction |
KR100894415B1 (en) | 2007-07-31 | 2009-04-24 | 동우당제약(주) | A method for making tea containing Liriope platyphylla WANG et TANG |
CN101543587A (en) | 2008-03-25 | 2009-09-30 | 林宝华 | Chinese herbal compound for treating multiple convulsion and pharmaceutical composition using same |
CN101554238A (en) | 2008-04-10 | 2009-10-14 | 刘泳宏 | Mind-tranquilizing brain-strengthening egg and preparing method thereof |
CN101601471A (en) * | 2008-06-11 | 2009-12-16 | 刘泳宏 | A kind of natural five-color bodybuilding herbal cuisine porridge and preparation method |
CN101926459A (en) | 2009-11-20 | 2010-12-29 | 张小夫 | Preparation for improving learning memory and preventing test anxiety and preparation method thereof |
CN101829280B (en) | 2010-05-19 | 2014-03-19 | 南宁市品迪生物工程有限公司 | Chinese medicinal herb formulation for preventing aypnia and promoting sweet sleep |
KR101189191B1 (en) | 2010-06-24 | 2012-10-09 | 한국과학기술연구원 | Composition comprising longan arillus extract or mixed extracts comprising the same for neurodegenerative diseases |
-
2012
- 2012-03-29 WO PCT/KR2012/002330 patent/WO2012134194A2/en active Application Filing
- 2012-03-29 CN CN201280016132.2A patent/CN103533948A/en active Pending
- 2012-03-29 EP EP12762802.2A patent/EP2691102B1/en active Active
- 2012-03-29 KR KR1020137026397A patent/KR101601860B1/en active IP Right Grant
- 2012-03-29 CN CN201811127563.1A patent/CN109568499A/en active Pending
- 2012-03-29 JP JP2014502473A patent/JP5832628B2/en active Active
- 2012-03-29 ES ES12762802T patent/ES2715290T3/en active Active
- 2012-03-29 US US14/007,095 patent/US10058583B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP2691102A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083490A (en) * | 2013-02-18 | 2013-05-08 | 柳少逸 | Traditional Chinese medicine for treating post-traumatic brain syndrome |
CN103272010A (en) * | 2013-06-11 | 2013-09-04 | 陈静静 | Traditional Chinese medicine formula for orthopedic nursing |
CN104920001A (en) * | 2014-03-20 | 2015-09-23 | 四川代代为本农业科技有限公司 | Stereo-planting method for interplanting climbing vegetables with ophiopogon japonicas |
Also Published As
Publication number | Publication date |
---|---|
CN103533948A (en) | 2014-01-22 |
CN109568499A (en) | 2019-04-05 |
US10058583B2 (en) | 2018-08-28 |
KR20130130069A (en) | 2013-11-29 |
JP2014510752A (en) | 2014-05-01 |
WO2012134194A3 (en) | 2013-03-21 |
EP2691102A4 (en) | 2014-11-05 |
EP2691102A2 (en) | 2014-02-05 |
US20140023677A1 (en) | 2014-01-23 |
JP5832628B2 (en) | 2015-12-16 |
ES2715290T3 (en) | 2019-06-03 |
KR101601860B1 (en) | 2016-03-09 |
EP2691102B1 (en) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10058583B2 (en) | Herbal compositions for treating neurological diseases and improving memory impairment | |
Muszyńska et al. | Natural products of relevance in the prevention and supportive treatment of depression | |
Abenavoli et al. | Milk thistle in liver diseases: past, present, future | |
Huang et al. | Acanthopanax senticosus: review of botany, chemistry and pharmacology | |
JP2020100657A (en) | Compositions, methods, and medical compositions for treatment of liver and maintaining health of liver | |
JP2018524363A (en) | Compositions, methods and pharmaceutical compositions for liver treatment and liver health maintenance | |
AU2016341452B2 (en) | A process to enhance the bioactivity of Ashwagandha extracts | |
Shakya | Drug-induced hepatotoxicity and hepatoprotective medicinal plants: a review | |
CN106135891A (en) | A kind of health food to alcoholic liver injury with defencive function | |
Sengupta et al. | Plant-derived natural products for Parkinson’s disease therapy | |
Haque et al. | A review on antidepressant effect of herbal drugs | |
Moreira et al. | The neuroprotective effect of traditional Chinese medicinal plants—A critical review | |
Pattewar et al. | Phytomedicines and cognition | |
Nandy et al. | Bacopa monnieri: The neuroprotective elixir from the East—Phytochemistry, pharmacology, and biotechnological improvement | |
CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
Dawada et al. | Hepatoprotective activity of Cassia fistula root against carbon tetrachloride-induced hepatic injury in rats (Wistar) | |
RU2408384C2 (en) | Chinese medicinal composition, method for preparing and administration | |
KR20170042139A (en) | Composition for Treatment or Prevention of Memory Disorder in Parkinson's Disease Comprising Gynostemma pentaphyllum Makino Extract or Gypenoside As Active Ingredient | |
KR101167628B1 (en) | A composition comprising black ginseng for treating or preventing dementia and improving cognitive function | |
KR101194974B1 (en) | A composition comprising the extract of Crataegus pinnatifida treating and preventing neuro-degenerative disease | |
Dhingra et al. | Neuroprotection of Multitargeted Phytochemicals against Alzheimer: A Desperate Need from Nature | |
ES2688844T3 (en) | Composition for the prevention and treatment of migraine or neuropathic pain | |
CN113842461B (en) | GABA for relieving and treating alcoholism and drunk discomfort A Receptor conjugates, compositions and uses thereof | |
Reddy | Madhunasini (Gymnema sylvestre): A miracle plant for diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12762802 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14007095 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014502473 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137026397 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012762802 Country of ref document: EP |